PolyPid Ltd. (PYPD) stock
Close on Nov 13, 2026Market cap $113.96MP/E 3.0Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $113.96M
- P/E ratio
- 3.0
- Price to sales
- –
- Price to book
- 21.15
- Dividend yield
- –
- Free cash flow yield
- -24.65%
Fundamentals
- Net income
- -$34.17M
- EPS, diluted
- $2.09
- Free cash flow
- -$28.09M
Trading
- Previous close
- $6.40
- Open
- $6.58
- Day's range
- $6.03 – $6.58
- Volume
- 193,158
- Average volume (20 days)
- 170,161
- Beta (5 years)
- 0.69
- 52-week range
- $3.50 – $7.15
- RSI (14 days)
- 63.6
- Volatility (1 year)
- 57.0%
- Relative volume
- 1.12×
- WACC
- 8.6%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | PYPD | S&P 500 | Difference | PYPD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +28.3% | -3.0% | +31.3 pts | ||
| 3 months | +31.0% | -2.8% | +33.7 pts | ||
| Year to date | +44.2% | +11.5% | +32.8 pts | ||
| 1 year | +74.9% | +13.5% | +61.4 pts | ||
| 3 years | +55.5% | +77.7% | −22.2 pts | +15.9% | +21.1% |
| 5 years | -97.3% | +72.6% | −169.9 pts | -51.4% | +11.5% |
Nine years at a glance
Fiscal years 2017 to 2025, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases PolyPid filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About PolyPid
Surgical & Medical Instruments & Apparatus
PolyPid Ltd. is a clinical-stage biopharmaceutical company focused on developing locally administered, controlled-release therapeutics to address unmet medical needs. Utilizing its proprietary PLEX drug delivery technology, the company designs treatments that continuously release therapeutic agents directly at surgical and disease sites over extended periods. Its lead investigational drug candidate, D-PLEX100, pairs PLEX with doxycycline to prevent surgical site infections, with an initial focus on patients undergoing abdominal colorectal surgeries. The company's pipeline also encompasses preclinical and early-stage development programs, including a long-acting subcutaneous delivery platform for GLP-1 receptor agonists and an intratumoral cancer therapy candidate known as OncoPLEX.
Company profile, executives and historyPolyPid stock: common questions
What is PolyPid's stock price?
PYPD closed at $6.26 on Nov 13, 2026, down 2.19% on the day. Over the past 52 weeks it traded between $3.50 and $7.15.
What is PolyPid's market cap?
PolyPid was worth $113.96M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is PYPD's P/E ratio?
PYPD trades at 3.0 times earnings, based on diluted earnings per share of $2.09 over fiscal 2025.
Does PolyPid pay a dividend?
No. PolyPid has not paid a cash dividend over the last twelve months.
How has PYPD stock performed over the past year?
Including dividends, PYPD returned +74.9% over the past year, against +13.5% for the S&P 500.
How many PYPD shares are sold short?
0M shares were sold short at the latest FINRA report, 9.16% of the float, or 3.5 days of average trading volume.
Who are PolyPid's competitors?
Companies most similar to PolyPid by business, industry and size include PLRZ, SGP, MBOT, DRTS, GUTS.
See a number that looks wrong?